Clinical Performance and Safety Assessment of the Use of iCover Balloon Expandable Covered Stent (iVascular) Implanted as Bridging Stent in FEVAR (Fenestrated Endovascular Aortic Repair) for the Treatment of Complex Abdominal Aortic Aneurysms

Exclusion Criteria

• •1. Patients contraindicated for anti-platelet therapy.
• •2. Patients with uncontrolled haematological disorders or heparin-induced thrombocytopenia.
• •3. Chronic or acute aortic dissection.
• •4. Patients refusing treatment.
• •5. Patients who are pregnant or wish to become pregnant.
• •6. Patients scheduled for major or life-saving surgery within 30 days of the fenestrated stent procedure.
• •7. Patients considered hemodynamically unstable or requiring emergency treatment.
• •8. Patients with severe arteriopathy leading to adverse outflow, which may impair bridging stent patency on the targeted artery.
• •9. Thrombus in the aortic sealing zone and target arteries with thickness \> to 3 mm.
• •10. Stenosis (\>50%) or occlusion of target arteries or distal disease resulting in poor iCover stent outflow.
• •11. Patients allergic to stent materials (L605) and/or PTFE.
• •12. Patients requiring a hybrid aortic technique with branches, semibranches or chimneys.
• •13. Patient who has been implanted with any stent type or brand other than iCover as a bridging stent in any target artery.
• •14. Patients with infectious/mycotic aneurysms.
• •15. Angulation between renal artery and aortic wall \< 30 degrees.
• •16. Patients with complex iliac accesses out the IFUs of the fenestrated endograft chosen to be implanted (COOK Medical / Terumo Aortic/Jotec-Artivion) with the iCover Bridging stent.
• •17. Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period that may interfere with the results of this study.
• •18. Myocardial infarction or stroke within 3 months prior to the procedure.
• •19. Patients with an unstable angina pectoris or heart insufficiency NYHA 3 or 4.
• •20. Patients with ASA classification 5 or higher.
• •21. Patients with physician modified endografts or in situ laser FEVAR.